Employment and Economic Outlook - The employment report is anticipated to show an increase in U.S. job growth despite a sluggish labor market, influenced by tariff uncertainty and tighter immigration enforcement [1][8] - Retail sales have stalled unexpectedly, raising the probability of an interest-rate reduction in April to 35.5% from 32.2% [1][8] - Markets are pricing in the first interest rate cut to occur in June, coinciding with the expected Senate approval of President Trump's Fed chair nominee, Kevin Warsh [2][8] Corporate Earnings and Market Reactions - Cloudflare's shares surged by 14% following a better-than-expected forecast for annual and first-quarter sales [5][8] - Robinhood's shares fell by 7.2% after reporting fourth-quarter revenue below Wall Street expectations [6][8] - Lyft's shares dropped 17% due to a quarterly profit forecast and annual ride volumes that did not meet Wall Street expectations [9][8] Legislative and Regulatory Developments - The U.S. House of Representatives rejected a Republican bid to block challenges to Trump's tariffs, potentially allowing Democrats to reverse tariffs imposed on Canada [7][8] - A Supreme Court ruling on the legality of the tariffs is expected in the coming months [7][9]

班塞尔指出："以FDA已批准的疫苗作为对照进行流感疫苗申报，且该研究方案在启动前已与CBER讨 论并达成一致，对此申请进行全面审评本不应存在争议。"该公司为mRNA-1010提交的上市申请包含两 项后期研究，这些研究均达到了试验的主要目标。 Moderna去年曾表示，其mRNA-1010疫苗比葛兰素史克(GSK.US)已获批的流感疫苗有效性高出26.6%。 该公司称已要求与FDA举行会议，以明确后续路径。 这一进展发生在美国全面修订其长期实施的儿童免疫指导方针，并撤回对包括流感在内的六种传染病常 规疫苗接种建议的一个多月后。Moderna在今年早些接受采访时表示，由于美国官员对疫苗接种的反对 声浪日益高涨，公司不打算投资新的后期疫苗临床试验。当前FDA已批准的流感疫苗包括阿斯利康 (AZN.US)和赛诺菲(SNY.US)生产的产品。 Moderna去年撤回了其流感-新冠联合疫苗的上市申请，以等待其流感疫苗后期试验的有效性数据。目前 该疫苗正在欧盟、加拿大和澳大利亚接受审评，公司预计有望在2026年底或2027年初获得批准。 智通财经APP获悉，Moderna(MRNA.US)周二表示，美国食品药品监督管理局( ...

Core Viewpoint - Moderna shares experienced a 14% decline in Frankfurt following the U.S. FDA's refusal to review the company's influenza vaccine approval application [1] Company Summary - Moderna's stock opened 14% lower in Frankfurt, indicating a significant market reaction to the FDA's decision [1] - The trading volume was low, suggesting limited investor activity during this period [1] Industry Summary - The refusal by the U.S. FDA to review the influenza vaccine application may impact the broader vaccine market and investor sentiment towards vaccine developers [1]

Activist investor Elliott has built a stake in the London Stock Exchange Group and is engaging with the company to drive performance, a person familiar with the matter told Reuters on Wednesday. ...

Moderna补充称，该疫苗先前已获得批准，FDA亦未有发现疫苗有任何具体的安全性及有效性问题，而 是对研究设计提出建议，预计FDA的最新决定不会影响公司今年的财务预期，该疫苗最快将于今年底或 明年底获得批准，具体时间取决于美国、欧洲、加拿大及澳洲的监管审查。(格隆汇) 疫苗生产商Moderna(MRNA.US)夜盘跌7.7%，报38.76美元。消息面上，美国食品药物管理局(FDA)拒绝 对Moderna的试验性流感疫苗mRNA-1010展开审查程序，显示美国政府收紧对美国疫苗的监管。 Moderna表示，FDA最新决定与此前公司提交申请并开始为mRNA-1010展开三期临床试验前所提供的意 见不一致，公司已要求与FDA会面以了解下一步行动。 ...

Moderna Inc (NASDAQ: MRNA )股价在周二盘后交易中大幅下跌，此前该公司表示美国食品药品监督管理局(FDA)拒绝审查其流感疫苗mRNA- 1010。 在公告发布后，Moderna股价最多下跌7%，至约39美元。 CBER批评Moderna将其疫苗与标准流感疫苗进行对比测试，认为这不能反映"最佳可用护理标准"。Moderna表示，该机构并未指出疫苗存在 任何具体的安全性或有效性问题。 Moderna表示，此举与该机构此前的指导不一致，并已要求与FDA会面以进一步推进。该公司提到了CBER负责人Vinay Prasad的评论——他 支持美国卫生部长Robert F. Kennedy Jr.对加强疫苗监管的呼吁。 Moderna还对FDA的理由提出异议，称该机构之前的指导并不要求临床试验必须使用最先进的可比治疗作为对照。 Moderna曾在2025年中表示，mRNA-1010疫苗在三期临床试验中达到了所有试验目标。该公司将这款疫苗定位为同时针对流感和COVID-19 的组合型流感疫苗。 该公司表示，FDA生物制品评估和研究中心(CBER)已通知Moderna，由于缺乏"充分且良好控制"的研究， ...

Group 1 - The company announced that the agency would not review its application due to insufficient testing in the study for the shot [1]

Economic Data - The US economy added 130,000 jobs in January, significantly exceeding expectations of 65,000 jobs added for the month [1][5] - The unemployment rate decreased slightly to 4.3% from 4.4% [1][6] - Revisions to 2025 payrolls showed a decrease in job growth to 181,000 from a previously reported 584,000, marking the weakest annual job growth outside of a recession since 2003 [2][6] Market Reactions - The tech-heavy Nasdaq Composite rose approximately 0.9%, while the Dow Jones Industrial Average increased by 0.6% (280 points), and the S&P 500 gained 0.7% [1] - The positive January jobs data has led to increased bets on Federal Reserve rate cuts, with over 40% of market participants expecting the Fed to hold rates steady through June [4] Corporate Earnings - McDonald's is set to report earnings after the market close, while Kraft Heinz announced a pause in its spin-off plans, indicating that its challenges are manageable [5][11] - Kraft Heinz plans to invest $600 million in marketing, sales, research and development, and pricing to accelerate its return to profitable growth [11][12] - Cisco is expected to report quarterly results, competing with Nvidia in the AI networking chip market [5]

The FDA has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said. https://t.co/mBu4Up1Lh5 ...

The FDA has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said. https://t.co/9wBbuFdMc1 ...